Cannabinoid mouth spray brought help to a severely spastic young man.

“Cannabinoid was licensed in 2012 for the treatment of spasticity associated with multiple sclerosis in Finland. Spasticity is one of the main symptoms in cerebral palsies and a risk factor of multiple painful anomalies of the skeletal network. We describe a 28-year-old man with severe cerebral palsy, whose quality of life improved and the need for help decreased by using two daily mouth sprays of cannabinoid.”

http://www.ncbi.nlm.nih.gov/pubmed/25158585

Leave a Reply

Your email address will not be published. Required fields are marked *